Skip to main content

Table 1 Summary of treatments performed in the BALB/c mice

From: Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice

Groups Route of administration Treatmentsa Mice number
    Total mice In HIband CMIc In challenged
I Intramuscular vaccination 100 μl PBS 10 3 7
   100 μg pVAX1 10 3 7
   100 μg pVAX1-MEG-CTXA2/B 10 3 7
II Intranasal vaccination 200 μl BRD509 10 3 7
   200 μl BRD509/pVAX1 10 3 7
   200 μl BRD509/pVAX1-MEG-CTXA2/B 10 3 7
III Intraoral vaccination 50 μl BRD509 10 3 7
   50 μl BRD509/pVAX1 10 3 7
   50 μl BRD509/pVAX1-MEG-CTXA2/B 10 3 7
  1. aThe mice were randomly divided into intramuscular, intranasal and intraoral immunization groups (30 mice per group). For the intramuscular group, the mice were injected 100 μl 1 μg/μl recombinant plasmid or empty plasmid in the quadriceps muscle; For the nasal group, each mouse was given a nasal drip of 50 μl 109 cfu/ml Salmonella bacteria with recombinant plasmid or empty plasmid; The oral group was administrated 200 μl 109 cfu / ml Salmonella bacteria with recombinant plasmid or empty plasmid orally; Each group also had 10 mice which were treated with Salmonella without plasmid or saline as negative control. Mice were vaccinated three times at 2 week intervals.
  2. bHumoral immunity (HI) was tested by collecting sera from three immunized mice in each group.
  3. cCellular immunity (CMI) was evaluated by splenocytes from three immunized mice per group 2 weeks after the last immunization.
  4. dFour weeks after the last immunization, immunized mice were challenged intraperitoneally with 1 × 103 tachyzoites of T. gondii RH strain.